3I14
Alternative Names: Pan-influenza A monoclonal antibody - AbViro/Integrated BioTherapeuticsLatest Information Update: 30 Jun 2023
At a glance
- Originator Integrated BioTherapeutics
- Developer AbViro; Integrated BioTherapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza A virus infections
Most Recent Events
- 12 Jun 2023 Preclinical trials in Influenza A virus infections in USA (unspecified route) (Integrated BioTherapeutics pipeline, June 2023)
- 12 Jun 2023 Integrated BioTherapeutics intends to file IND application (Integrated BioTherapeutics pipeline, June 2023)